FY2028 EPS Estimates for CRSP Decreased by Analyst

Key Points

• Brookline Capital Markets cut its FY2028 EPS estimate for CRISPR Therapeutics to $6.91 from $7.44, while the current consensus for the company's full-year EPS remains negative at ($4.93) per share.
• CRISPR reported Q1 EPS of ($1.28), missing the ($1.22) estimate, and revenue of $1.46 million versus a $6.06 million forecast — revenue rose 68.6% year-over-year but the company shows steep negative margins and a negative return on equity.
• Analysts' consensus rating is a "Moderate Buy" with a $64.53 target price, but insiders (including the CEO and general counsel) have recently sold shares — 51,828 shares sold in the past 90 days.

CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) - Equities research analysts at Brookline Capital Markets dropped their FY2028 earnings per share estimates for CRISPR Therapeutics in a research note issued on Tuesday, May 5th. Brookline Capital Markets analyst L. Cann now forecasts that the company will post earnings of $6.91 per share for the year, down from their prior forecast of $7.44. The consensus estimate for CRISPR Therapeutics' current full-year earnings is ($4.93) per share.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($1.28) EPS for the quarter, missing analysts' consensus estimates of ($1.22) by ($0.06). The company had revenue of $1.46 million for the quarter, compared to analyst estimates of $6.06 million. CRISPR Therapeutics had a negative return on equity of 25.53% and a negative net margin of 13,856.54%.The company's revenue for the quarter was up 68.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($1.58) EPS.

A number of other brokerages have also recently commented on CRSP. Piper Sandler restated an "overweight" rating and set a $110.00 price objective (up from $105.00) on shares of CRISPR Therapeutics in a research note on Tuesday, March 17th. Bank of America dropped their target price on CRISPR Therapeutics from $90.00 to $89.00 and set a "buy" rating on the stock in a research report on Thursday, January 22nd. Citizens Jmp dropped their target price on CRISPR Therapeutics from $86.00 to $80.00 and set a "market outperform" rating on the stock in a research report on Friday, January 30th. TD Cowen lifted their target price on CRISPR Therapeutics from $40.00 to $45.00 and gave the stock a "hold" rating in a research report on Friday, February 13th. Finally, Morgan Stanley reaffirmed an "underweight" rating and set a $33.00 target price on shares of CRISPR Therapeutics in a research report on Tuesday, February 17th. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, six have assigned a Hold rating and two have assigned a Sell rating to the company's stock. According to MarketBeat, CRISPR Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $64.53.

CRISPR Therapeutics Price Performance

Shares of CRSP opened at $52.38 on Wednesday. The stock's 50-day moving average is $52.41 and its two-hundred day moving average is $54.60. The stock has a market cap of $5.05 billion, a PE ratio of -8.42 and a beta of 1.74. CRISPR Therapeutics has a 12 month low of $33.03 and a 12 month high of $78.48.

Insider Transactions at CRISPR Therapeutics

In related news, General Counsel James R. Kasinger sold 3,182 shares of the business's stock in a transaction dated Monday, March 23rd. The stock was sold at an average price of $46.78, for a total value of $148,853.96. Following the completion of the sale, the general counsel directly owned 94,308 shares of the company's stock, valued at $4,411,728.24. The trade was a 3.26% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Samarth Kulkarni sold 10,020 shares of the business's stock in a transaction dated Monday, March 23rd. The shares were sold at an average price of $46.78, for a total value of $468,735.60. Following the completion of the sale, the chief executive officer directly owned 255,501 shares of the company's stock, valued at approximately $11,952,336.78. This represents a 3.77% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 51,828 shares of company stock valued at $2,578,097. 4.10% of the stock is currently owned by insiders.

Hedge Funds Weigh In On CRISPR Therapeutics

Institutional investors have recently made changes to their positions in the stock. Mcguire Capital Advisors Inc. bought a new position in shares of CRISPR Therapeutics during the fourth quarter valued at approximately $25,000. Ramirez Asset Management Inc. bought a new position in shares of CRISPR Therapeutics during the fourth quarter valued at approximately $26,000. Rothschild Investment LLC grew its holdings in shares of CRISPR Therapeutics by 836.7% during the fourth quarter. Rothschild Investment LLC now owns 562 shares of the company's stock valued at $29,000 after purchasing an additional 502 shares during the last quarter. Thurston Springer Miller Herd & Titak Inc. grew its holdings in shares of CRISPR Therapeutics by 196.9% during the fourth quarter. Thurston Springer Miller Herd & Titak Inc. now owns 576 shares of the company's stock valued at $30,000 after purchasing an additional 382 shares during the last quarter. Finally, Optiver Holding B.V. grew its holdings in shares of CRISPR Therapeutics by 71.4% during the third quarter. Optiver Holding B.V. now owns 504 shares of the company's stock valued at $33,000 after purchasing an additional 210 shares during the last quarter. 69.20% of the stock is owned by institutional investors.

About CRISPR Therapeutics

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.